RxDoctor Payments Data

Carolyn Fegenbush

Nurse Practitioner · Jeffersonville, INNPI 1629009790

Payments from drug & device makers

$1,482in general payments, 2019–2025

Across 94 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$282
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$149
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
  • Lilly USA, LLC$107
  • Tris Pharma Inc$102
  • Otsuka America Pharmaceutical, Inc.$102
  • plus $603 from 14 others

What the payments were for

  • Food & beverage$1,482100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,482 in reported general payments places this provider in the 75th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$47,804
Medicare patients
24
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate12$197,818
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,248
OzempicSemaglutide12$13,382
EliquisApixaban18$10,901
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl121$3,748
Meropenem-0.9% NaclMeropenem-0.9% Sodium Chloride11$3,642
Levetiracetam14$2,356
Baclofen42$1,362
Vilazodone Hcl15$1,252
Glycopyrrolate11$1,006
Gabapentin85$984
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$445
Ondansetron Hcl13$442
Buspirone Hcl30$421
Ibuprofen24$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$99$17,24826 claims
Novo NordiskOzempic$12$13,38212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →